285 related articles for article (PubMed ID: 31919759)
1. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
Iglesias-Santamaría A
Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
3. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
[TBL] [Abstract][Full Text] [Related]
5. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
6. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
[TBL] [Abstract][Full Text] [Related]
7. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
9. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Yu Y; Zheng P; Gao L; Li H; Tao P; Wang D; Ding F; Shi Q; Chen H
J Immunother; 2021 Feb-Mar 01; 44(2):76-85. PubMed ID: 33208635
[TBL] [Abstract][Full Text] [Related]
10. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
[TBL] [Abstract][Full Text] [Related]
11. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
Elkrief A; Derosa L; Kroemer G; Zitvogel L; Routy B
Ann Oncol; 2019 Oct; 30(10):1572-1579. PubMed ID: 31268133
[TBL] [Abstract][Full Text] [Related]
12. Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
Chambers LM; Michener CM; Rose PG; Reizes O; Yao M; Vargas R
Gynecol Oncol; 2021 Apr; 161(1):211-220. PubMed ID: 33504455
[TBL] [Abstract][Full Text] [Related]
13. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.
Mohiuddin JJ; Chu B; Facciabene A; Poirier K; Wang X; Doucette A; Zheng C; Xu W; Anstadt EJ; Amaravadi RK; Karakousis GC; Mitchell TC; Huang AC; Shabason JE; Lin A; Swisher-McClure S; Maity A; Schuchter LM; Lukens JN
J Natl Cancer Inst; 2021 Feb; 113(2):162-170. PubMed ID: 32294209
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.
Elkrief A; El Raichani L; Richard C; Messaoudene M; Belkaid W; Malo J; Belanger K; Miller W; Jamal R; Letarte N; Wong P; Routy B
Oncoimmunology; 2019; 8(4):e1568812. PubMed ID: 30906663
[No Abstract] [Full Text] [Related]
15. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
16. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M; Mauric E; Tison A; Barnetche T; Barre A; Nikolski M; Rouxel L; Dutriaux C; Dousset L; Prey S; Beylot-Barry M; Seneschal J; Veillon R; Vergnenegre C; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Ravaud A; Forcade E; Schaeverbeke T;
Eur J Cancer; 2021 Nov; 157():474-484. PubMed ID: 34649118
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
[TBL] [Abstract][Full Text] [Related]
18. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D; Hoyd R; Muniak M; Husain M; Bassett JS; Wang L; Tinoco G; Patel SH; Burkart J; Miah A; Li M; Johns A; Grogan M; Carbone DP; Verschraegen CF; Kendra KL; Otterson GA; Li L; Presley CJ; Owen DH
BMC Cancer; 2020 May; 20(1):383. PubMed ID: 32375706
[TBL] [Abstract][Full Text] [Related]
19. Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy.
Zhong J; Xiong D; Liu Y; Yuan S
Thorac Cancer; 2024 Jan; 15(2):152-162. PubMed ID: 38010059
[TBL] [Abstract][Full Text] [Related]
20. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
